Company intelligence / Profile preview

Roger New

London, England, United Kingdomrogerraglin.com ↗

Ownership: Private
Development stage: Other

Overview

Proxima Concepts has developed several innovative drug delivery and discovery platforms. Their oral insulin formulation has reached Phase II clinical trials and been licensed out. Their oral vaccine carrier system has demonstrated efficacy against multiple pathogens in animal models. A novel peptide therapy for rheumatoid arthritis is currently undergoing preclinical evaluation.

Therapeutic areas: EndocrinologyImmunologyInfectious Diseases
Modalities: PeptidesOral vaccine technologyLiposomal drug delivery
Industry: Biotech

Partnerships

Large pharmaceutical partner licensing the oral insulin product (name not disclosed)

Beyond the preview

Go deeper on Roger New.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Roger New.

Explore the full profile